Cubist, Merck deal

Merck will acquire Cubist for $102 per share and $1.1 billion in assumption of debt in a deal

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE